CN104013599B - 一种肿瘤特异性靶向给药的药物载体及其应用 - Google Patents
一种肿瘤特异性靶向给药的药物载体及其应用 Download PDFInfo
- Publication number
- CN104013599B CN104013599B CN201410230829.0A CN201410230829A CN104013599B CN 104013599 B CN104013599 B CN 104013599B CN 201410230829 A CN201410230829 A CN 201410230829A CN 104013599 B CN104013599 B CN 104013599B
- Authority
- CN
- China
- Prior art keywords
- tumor
- heavy chain
- hfn
- dox
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 124
- 239000003937 drug carrier Substances 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 119
- 239000002105 nanoparticle Substances 0.000 claims abstract description 47
- 102000008857 Ferritin Human genes 0.000 claims abstract description 43
- 108050000784 Ferritin Proteins 0.000 claims abstract description 43
- 238000008416 Ferritin Methods 0.000 claims abstract description 41
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 29
- 238000012377 drug delivery Methods 0.000 claims abstract description 9
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 8
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical group C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 35
- 229930195573 Amycin Natural products 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 30
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004202 carbamide Substances 0.000 claims description 14
- 210000003462 vein Anatomy 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 238000001361 intraarterial administration Methods 0.000 claims description 3
- 230000001926 lymphatic effect Effects 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 201000001514 prostate carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000000777 hematopoietic system Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000005075 mammary gland Anatomy 0.000 claims description 2
- 201000010174 renal carcinoma Diseases 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 4
- 108010002084 Apoferritins Proteins 0.000 description 44
- 102000000546 Apoferritins Human genes 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 35
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 32
- 210000004881 tumor cell Anatomy 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 238000011068 loading method Methods 0.000 description 19
- 238000002372 labelling Methods 0.000 description 18
- 229940079593 drug Drugs 0.000 description 15
- 238000011160 research Methods 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 210000000056 organ Anatomy 0.000 description 14
- 230000008685 targeting Effects 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- 108050003222 Transferrin receptor protein 1 Proteins 0.000 description 10
- 229960004679 doxorubicin Drugs 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 7
- 229940115080 doxil Drugs 0.000 description 7
- 210000003712 lysosome Anatomy 0.000 description 7
- 230000001868 lysosomic effect Effects 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HPZOOQSXPMEJBV-ODCFVKFUSA-N Tirilazad mesylate Chemical compound CS(O)(=O)=O.O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 HPZOOQSXPMEJBV-ODCFVKFUSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 241000209094 Oryza Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 231100000682 maximum tolerated dose Toxicity 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940009456 adriamycin Drugs 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002539 nanocarrier Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000001163 endosome Anatomy 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 238000010528 free radical solution polymerization reaction Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 238000004153 renaturation Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 101000802478 Sylvirana guentheri Brevinin-2GHa Proteins 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009513 drug distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101710157275 Ferritin subunit Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940021171 curative drug Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000008290 endocytic mechanism Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- -1 more than 6M) Chemical compound 0.000 description 1
- 239000002091 nanocage Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (9)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410230829.0A CN104013599B (zh) | 2014-05-28 | 2014-05-28 | 一种肿瘤特异性靶向给药的药物载体及其应用 |
EP14893412.8A EP3150202A4 (en) | 2014-05-28 | 2014-09-24 | Drug carrier for tumour-specific targeted drug delivery and use thereof |
JP2016569947A JP6294510B2 (ja) | 2014-05-28 | 2014-09-24 | 腫瘍特異性標的投与の薬物キャリア及びその応用 |
US15/314,307 US10195155B2 (en) | 2014-05-28 | 2014-09-24 | Drug carrier for tumor-specific targeted drug delivery and use thereof |
PCT/CN2014/087286 WO2015180325A1 (zh) | 2014-05-28 | 2014-09-24 | 一种肿瘤特异性靶向给药的药物载体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410230829.0A CN104013599B (zh) | 2014-05-28 | 2014-05-28 | 一种肿瘤特异性靶向给药的药物载体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104013599A CN104013599A (zh) | 2014-09-03 |
CN104013599B true CN104013599B (zh) | 2016-11-23 |
Family
ID=51430785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410230829.0A Active CN104013599B (zh) | 2014-05-28 | 2014-05-28 | 一种肿瘤特异性靶向给药的药物载体及其应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10195155B2 (zh) |
EP (1) | EP3150202A4 (zh) |
JP (1) | JP6294510B2 (zh) |
CN (1) | CN104013599B (zh) |
WO (1) | WO2015180325A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104013599B (zh) * | 2014-05-28 | 2016-11-23 | 中国科学院生物物理研究所 | 一种肿瘤特异性靶向给药的药物载体及其应用 |
DK3186192T3 (en) * | 2014-09-30 | 2018-04-23 | Thena Biotech S R L | FUSION PROTEIN, NANOPARTICLE CONSISTS OF A MULTIPLE OF MONOMERS OF THE FUSION PROTEIN AND APPLICATIONS THEREOF |
CN105560214B (zh) * | 2014-10-16 | 2018-10-19 | 倪健 | 抗人表皮生长因子受体2单克隆抗体结合纳米胶束及其制备与应用 |
CN108503704A (zh) | 2017-02-27 | 2018-09-07 | 昆山新蕴达生物科技有限公司 | 穿越血脑屏障的纳米药物载体 |
CN108976299B (zh) * | 2017-06-05 | 2020-02-14 | 昆山新蕴达生物科技有限公司 | 一种改善抗体片段亲和力和体内半衰期的方法 |
CN110237262B (zh) * | 2018-03-07 | 2021-06-08 | 昆山新蕴达生物科技有限公司 | HFn包载铂类药物的方法及其产物 |
CN110237047B (zh) * | 2018-03-07 | 2021-12-21 | 昆山新蕴达生物科技有限公司 | 铁蛋白包载药物的方法及其产物 |
CN110237263B (zh) * | 2018-03-07 | 2022-06-17 | 昆山新蕴达生物科技有限公司 | HFn包载阿霉素的方法及其产物 |
CN110179997B (zh) * | 2018-08-08 | 2020-02-14 | 昆山新蕴达生物科技有限公司 | 一种用于糖尿病治疗的纳米药物载体及其组合药物 |
CN109512799B (zh) * | 2019-01-17 | 2021-06-15 | 中国科学院生物物理研究所 | 一种装载抗肿瘤药物的纳米药物载体、其制备方法及应用 |
CN112107556A (zh) * | 2019-06-03 | 2020-12-22 | 北京大学 | 一种含砷纳米药物及其制备方法 |
CN112439079B (zh) * | 2019-08-30 | 2024-04-12 | 昆山新蕴达生物科技有限公司 | 有机溶剂法制备载药笼状蛋白 |
CN111603564B (zh) * | 2020-06-03 | 2023-05-05 | 太原师范学院 | 一种y型分子筛-阿霉素纳米药物及其制备方法和应用 |
CN112791185B (zh) * | 2021-01-20 | 2022-07-08 | 广州医科大学 | 用于肿瘤光热联合铁剂治疗纳米药物及其制备方法 |
CN112773900A (zh) * | 2021-02-03 | 2021-05-11 | 上海大学 | 一种肿瘤药物靶向载体及其制备方法与应用 |
CN113476588B (zh) * | 2021-07-06 | 2022-11-22 | 武汉大学 | 靶向乳腺癌的多功能纳米颗粒、其制备方法及其应用 |
CN114259563B (zh) * | 2021-12-27 | 2023-07-21 | 大连大学 | 一种硼递送剂及其制备方法 |
CN114668771B (zh) * | 2022-03-18 | 2022-12-06 | 南京林业大学 | 一种共载阿霉素和熊果酸的铁蛋白纳米粒的制备方法及应用 |
CN114732915B (zh) * | 2022-04-12 | 2023-08-29 | 上海交通大学 | 用于结肠癌的主动靶向治疗的纳米颗粒及制备方法、应用 |
CN114886873B (zh) * | 2022-06-15 | 2023-03-24 | 南京林业大学 | 一种负载sn-38的铁蛋白纳米粒及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101942022A (zh) * | 2010-07-29 | 2011-01-12 | 华东理工大学 | 抗人表皮生长因子受体单链抗体-铁蛋白重链亚基蛋白、构建方法及其用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8088392B2 (en) * | 2007-06-18 | 2012-01-03 | Yunxu Cao | Capsid proteins and uses therefore |
CN102778567B (zh) * | 2011-05-12 | 2015-05-06 | 中国科学院生物物理研究所 | 一种双功能肿瘤诊断试剂及方法 |
US20150093335A1 (en) * | 2012-01-19 | 2015-04-02 | Institute Of Geology And Geophysics, Chinese Academy Of Sciences | Cell-targeted magnetic nano-material and biomedical uses thereof |
CN104013599B (zh) | 2014-05-28 | 2016-11-23 | 中国科学院生物物理研究所 | 一种肿瘤特异性靶向给药的药物载体及其应用 |
-
2014
- 2014-05-28 CN CN201410230829.0A patent/CN104013599B/zh active Active
- 2014-09-24 WO PCT/CN2014/087286 patent/WO2015180325A1/zh active Application Filing
- 2014-09-24 JP JP2016569947A patent/JP6294510B2/ja active Active
- 2014-09-24 EP EP14893412.8A patent/EP3150202A4/en not_active Withdrawn
- 2014-09-24 US US15/314,307 patent/US10195155B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101942022A (zh) * | 2010-07-29 | 2011-01-12 | 华东理工大学 | 抗人表皮生长因子受体单链抗体-铁蛋白重链亚基蛋白、构建方法及其用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2015180325A1 (zh) | 2015-12-03 |
US20170189343A1 (en) | 2017-07-06 |
JP2017521376A (ja) | 2017-08-03 |
EP3150202A4 (en) | 2018-01-10 |
US10195155B2 (en) | 2019-02-05 |
CN104013599A (zh) | 2014-09-03 |
EP3150202A1 (en) | 2017-04-05 |
JP6294510B2 (ja) | 2018-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104013599B (zh) | 一种肿瘤特异性靶向给药的药物载体及其应用 | |
Ding et al. | Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy | |
Browning et al. | Drug delivery strategies for platinum-based chemotherapy | |
Sun et al. | Transferrin receptor-targeted PEG-PLA polymeric micelles for chemotherapy against glioblastoma multiforme | |
Popovtzer et al. | Actively targeted gold nanoparticles as novel radiosensitizer agents: an in vivo head and neck cancer model | |
Zheng et al. | Her2-targeted multifunctional nano-theranostic platform mediates tumor microenvironment remodeling and immune activation for breast cancer treatment | |
Goodwin et al. | Local and transient gene expression primes the liver to resist cancer metastasis | |
Son et al. | Folate-modified PLGA nanoparticles for tumor-targeted delivery of pheophorbide a in vivo | |
Wahab et al. | Current trends and future perspectives of nanomedicine for the management of colon cancer | |
CN108354901A (zh) | 用于肿瘤化疗与光热联合治疗的pH/还原双重敏感多功能纳米胶束及其应用 | |
Liu et al. | Ultrasound-mediated destruction of paclitaxel and oxygen loaded lipid microbubbles for combination therapy in ovarian cancer xenografts | |
He et al. | Design of multifunctional magnetic iron oxide nanoparticles/mitoxantrone-loaded liposomes for both magnetic resonance imaging and targeted cancer therapy | |
EP2860193B1 (en) | Polypeptide with function of targeted diagnosis and therapy of nasopharyngeal carcinoma, nanoparticles carrying same and use thereof | |
Wen et al. | Erythrocyte membrane-camouflaged gefitinib/albumin nanoparticles for tumor imaging and targeted therapy against lung cancer | |
Li et al. | Anti-ICAM-1 antibody-modified nanostructured lipid carriers: a pulmonary vascular endothelium-targeted device for acute lung injury therapy | |
Lainé et al. | Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules | |
Qiu et al. | Drug delivery system based on dendritic nanoparticles for enhancement of intravesical instillation | |
Ding et al. | Platinum-crosslinking polymeric nanoparticle for synergetic chemoradiotherapy of nasopharyngeal carcinoma | |
Li et al. | iRGD peptide-mediated liposomal nanoparticles with photoacoustic/ultrasound dual-modality imaging for precision theranostics against hepatocellular carcinoma | |
Liang et al. | Hybrid membrane-camouflaged hollow prussian blue nanoparticles for shikonin loading and combined chemo/photothermal therapy of metastatic TNBC | |
Liu et al. | RGD peptide-conjugated selenium nanocomposite inhibits human glioma growth by triggering mitochondrial dysfunction and ROS-dependent MAPKs activation | |
Yang et al. | Cetuximab-modified human serum albumin nanoparticles co-loaded with doxorubicin and MDR1 siRNA for the treatment of drug-resistant breast tumors | |
Fan et al. | Epidermal growth factor receptor-targeted peptide conjugated phospholipid micelles for doxorubicin delivery | |
Wang et al. | AY 1 receptor ligand synergized with a P-glycoprotein inhibitor improves the therapeutic efficacy of multidrug resistant breast cancer | |
Liu et al. | A therapeutic sheep in metastatic wolf’s clothing: Trojan horse approach for cancer brain metastases treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180102 Address after: 100081 building 201, No. 15, Haidian Zhongjie, Haidian District, Beijing, 201 Patentee after: Zhongke Xin Yun Bio Technology (Beijing) Co., Ltd. Address before: 100101 Beijing city Chaoyang District Datun Road No. 15 Patentee before: Institute of Biophysics, Chinese Academy of Sciences |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 215316 unit 305-1, building 6, No. 168, Yuanfeng Road, Yushan Town, Kunshan City, Suzhou City, Jiangsu Province Patentee after: Zhongke Xinyun Biotechnology (Kunshan) Co., Ltd Address before: 100081 building 201, No. 15, Haidian Zhongjie, Haidian District, Beijing, 201 Patentee before: Zhongke Xinyun Biotechnology (Beijing) Co., Ltd. |